1op9
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1op9.jpg|left|200px]] | [[Image:1op9.jpg|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1op9", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | + | --> | |
| - | + | {{STRUCTURE_1op9| PDB=1op9 | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Complex of human lysozyme with camelid VHH HL6 antibody fragment''' | '''Complex of human lysozyme with camelid VHH HL6 antibody fragment''' | ||
| Line 42: | Line 39: | ||
[[Category: Spencer, A.]] | [[Category: Spencer, A.]] | ||
[[Category: Wyns, L.]] | [[Category: Wyns, L.]] | ||
| - | [[Category: | + | [[Category: Amyloid fibril formation inhibition]] |
| - | [[Category: | + | [[Category: Antigen-antibody complex]] |
| - | [[Category: | + | [[Category: Immunoglobulin]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 04:07:15 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 01:07, 3 May 2008
Complex of human lysozyme with camelid VHH HL6 antibody fragment
Overview
Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues, often with serious pathological consequences. Non-neuropathic systemic amyloidosis is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases.
About this Structure
1OP9 is a Single protein structure of sequence from Camelus dromedarius and Homo sapiens. Full crystallographic information is available from OCA.
Reference
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme., Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, Wyns L, Redfield C, Matagne A, Robinson CV, Dobson CM, Nature. 2003 Aug 14;424(6950):783-8. PMID:12917687 Page seeded by OCA on Sat May 3 04:07:15 2008
Categories: Camelus dromedarius | Homo sapiens | Lysozyme | Single protein | Archer, D B. | Canet, D. | Decanniere, K. | Desmyter, A. | Dobson, C M. | Dumoulin, M. | Larsson, G. | Last, A M. | Matagne, A. | Muyldermans, S. | Redfield, C. | Robinson, C V. | Sasse, J. | Spencer, A. | Wyns, L. | Amyloid fibril formation inhibition | Antigen-antibody complex | Immunoglobulin
